Focused on new deals, Biogen bags a PhIII drug for ischemic stroke with $120M upfront
Biogen’s business development team has been on the march.
The big biotech has struck a deal to buy a Phase III drug for ischemic stroke …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
